Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967692 · ClinicalTrials.gov registry record · Phase 3
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 568
- Enrollment target
NCT02967692 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 568 participants.
The verdict
NCT02967692, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 568 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.
Interventions
- OTHER Placebo
- DRUG Trametinib
- DRUG Dabrafenib
- BIOLOGICAL Spartalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 568 participants |
| Start Date | 2017-02-17 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02967692
The ClinicalTrials.gov registry entry for NCT02967692 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02967692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02967692 about?
NCT02967692 is a clinical study titled "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma". The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable and metastatic melanoma.
What is the current status of trial NCT02967692?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 568 participants. The study started on 2017-02-17. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT02967692?
The interventions under investigation include: Placebo (OTHER), Trametinib (DRUG), Dabrafenib (DRUG), Spartalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02967692?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.